Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ET
Company Participants
Alina Venezia – Director of Investor Relations
Sheldon Koenig – President and Chief Executive Officer
Ben Halladay – Chief Financial Officer
Eric Warren – Chief Commercial Officer
Conference Call Participants
Dennis Ding – Jefferies
Joseph Pantginis – H.C. Wainwright
Thomas Shrader – BTIG
Tanmay Patwardhan – JPMorgan
Jason Zemansky – Bank of America
Serge Belanger – Needham
Paul Choi – Goldman Sachs
Kristen Kluska – Cantor Fitzgerald
Operator
Ladies and gentlemen, thank you for standing by, and welcome. At this time, all participants are in a listen-only mode. Following the presentation, there will be a question-and-answer session. Please be advised that today’s conference call may be recorded.
I would now like to turn the call over to Alina Venezia, Director of Investor Relations for Esperion Therapeutics. You may begin.
Alina Venezia
Thank you, operator. Good morning and welcome to Esperion’s fourth quarter and full year 2024 earnings conference call. With us on today’s call are Sheldon Koenig, President and CEO; and Ben Halladay, CFO. Other members of the executive team will be available for Q&A following our prepared remarks.
We issued a press release earlier this morning detailing the content of today’s call. A copy can be found on the Investor page of our website together with a copy of the presentation that we will also be referencing. I want to remind callers that the information discussed on the call today is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act.
I caution listeners that management will be making forward-looking statements. Actual results could differ materially from those stated or implied by our forward-looking statements due to the risks and uncertainties associated with the business. These forward-looking statements are qualified in
Read the full article here